Angela L Hill

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. pmc Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
    Angela L Hill
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    BMC Psychiatry 11:28. 2011
  2. ncbi Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation
    Robert W Baker
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285
    J Clin Psychopharmacol 23:342-8. 2003
  3. ncbi Dose response and atypical antipsychotics in schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    CNS Drugs 18:597-616. 2004
  4. doi Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine
    Angela L Hill
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225
    Clin Schizophr Relat Psychoses 7:216-22. 2014
  5. ncbi Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Int J Neuropsychopharmacol 6:97-102. 2003

Detail Information

Publications5

  1. pmc Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
    Angela L Hill
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    BMC Psychiatry 11:28. 2011
    ..2010), apparent dose-associated changes were noted in both efficacy and safety parameters. To help clinicians balance safety and efficacy when choosing a dose of olanzapine LAI, we further studied these changes...
  2. ncbi Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation
    Robert W Baker
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285
    J Clin Psychopharmacol 23:342-8. 2003
    ..Rapid assessment and effective treatment are necessary to manage agitation and, potentially, to shorten the time to recovery...
  3. ncbi Dose response and atypical antipsychotics in schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    CNS Drugs 18:597-616. 2004
    ..Furthermore, the higher doses are not associated with a significantly increased incidence of adverse events. Further studies are clearly needed to fully characterise the dose-response relationships of atypical antipsychotics...
  4. doi Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine
    Angela L Hill
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225
    Clin Schizophr Relat Psychoses 7:216-22. 2014
    ..Accordingly, the objective of the current analyses was to compare the incidences of EPS during treatment with olanzapine LAI versus oral olanzapine...
  5. ncbi Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Int J Neuropsychopharmacol 6:97-102. 2003
    ..05). Olanzapine orally disintegrating tablets were well-tolerated. Olanzapine orally disintegrating tablets may benefit acutely ill, non-compliant schizophrenic patients by facilitating acceptance of active antipsychotic drug therapy...